Ying Wang

Ying Wang is a Principal Scientist at Innoviva Specialty Therapeutics, Inc., focusing on quality control roles for commercial drug substances and drug products, and overseeing analytical methods and stability in various CROs and CMOs while contributing to regulatory filings since April 2023. Prior experience includes serving as Principal Scientist at Entasis Therapeutics, overseeing global analytical activities to ensure regulatory compliance, and as Senior Analytical Scientist I at Curia, where responsibilities included method development and supervising junior scientists. Ying Wang also has a strong background in scientific research, having worked at LI-COR Biosciences on chromatographic methods for imaging probes, at the University of Michigan on amyloid peptide analysis, and at Wayne State University and the Weizmann Institute of Science on molecular synthesis and groundwater remediation. Educational qualifications include a Ph.D. in Analytical Chemistry from Hunan University.